Phibro Animal Health lifts Q1 sales and EBITDA, keeps FY27 guidance
Phibro Animal Health reported Q1 FY27 sales up 6% and adjusted EBITDA up 4%, while its full-year guidance was maintained.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to TradingView, Phibro Animal Health (PAHC) reported first-quarter fiscal 2027 sales up 6% and adjusted EBITDA up 4%. The growth was led by Mineral Nutrition and Performance Products, where sales rose 17% and 16% respectively. The Animal Health segment, by contrast, saw adjusted EBITDA dip 1%.
The company kept its FY27 guidance unchanged. The report linked this to soft protein producer margins, uncertain timing of virginiamycin shipments in Brazil, and a focus on reducing inventory.
why it matters
Two points matter for the market: margin pressure among protein producers and uncertainty over Brazilian shipments. Higher sales with unchanged guidance signals stability, but not an upgrade to expectations.
market impact
PAHC shares: higher sales and EBITDA support the stock, while margin pressure limits upside
- PAHC shares mixed — higher sales and EBITDA are offset by margin pressure and unchanged guidance
tags
instruments
sources
- PAHC: Sales and adjusted EBITDA grew, while FY27 guidance held amid producer-margin pressure — TradingView, 5 November 2026 at 15:13 UTC
- PAHC: Q1 sales and adjusted EBITDA grew; FY27 guidance held steady — TradingView, 5 November 2026 at 16:12 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗